3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:百万円)

 

前連結会計年度

(2025年7月31日)

当連結会計年度

(2026年7月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

9,157

7,791

受取手形及び売掛金

5,038

3,916

電子記録債権

247

74

商品及び製品

6,311

7,533

仕掛品

675

820

原材料及び貯蔵品

864

790

その他

1,576

2,102

貸倒引当金

△0

△0

流動資産合計

23,870

23,029

固定資産

 

 

有形固定資産

 

 

建物及び構築物(純額)

2,082

2,068

機械装置及び運搬具(純額)

708

619

工具、器具及び備品(純額)

518

441

土地

1,194

1,196

リース資産(純額)

27

20

建設仮勘定

164

3,671

有形固定資産合計

4,696

8,018

無形固定資産

 

 

のれん

71

37

その他

49

48

無形固定資産合計

120

85

投資その他の資産

 

 

投資有価証券

2,450

2,670

繰延税金資産

515

630

その他

996

681

投資その他の資産合計

3,961

3,982

固定資産合計

8,778

12,085

資産合計

32,649

35,115

 

 

 

 

(単位:百万円)

 

前連結会計年度

(2025年7月31日)

当連結会計年度

(2026年7月31日)

負債の部

 

 

流動負債

 

 

支払手形及び買掛金

1,923

1,413

短期借入金

11,400

13,400

1年内返済予定の長期借入金

560

560

未払金

3,520

1,292

未払法人税等

1,494

418

賞与引当金

72

74

その他

1,034

1,107

流動負債合計

20,005

18,265

固定負債

 

 

長期借入金

671

3,211

退職給付に係る負債

378

374

その他

45

96

固定負債合計

1,096

3,682

負債合計

21,101

21,948

純資産の部

 

 

株主資本

 

 

資本金

2,043

2,043

資本剰余金

1,814

1,814

利益剰余金

7,691

8,969

自己株式

△195

△26

株主資本合計

11,353

12,800

その他の包括利益累計額

 

 

その他有価証券評価差額金

193

365

その他の包括利益累計額合計

193

365

純資産合計

11,547

13,166

負債純資産合計

32,649

35,115

 

E0248429290株式会社ファーマフーズ通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-08-012026-07-31FY2026-07-312024-08-012025-07-312025-07-311falsefalsefalse292902025-08-012026-07-31jppfs_cor:CapitalStockMember292902025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902025-07-31jppfs_cor:ShareholdersEquityMember292902025-07-31jppfs_cor:TreasuryStockMember292902025-07-31jppfs_cor:RetainedEarningsMember292902025-07-31jppfs_cor:CapitalSurplusMember292902025-07-31jppfs_cor:CapitalStockMember292902026-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902026-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902026-07-31jppfs_cor:ShareholdersEquityMember292902026-07-31jppfs_cor:TreasuryStockMember292902026-07-31jppfs_cor:RetainedEarningsMember292902026-07-31jppfs_cor:CapitalSurplusMember292902026-07-31jppfs_cor:CapitalStockMember292902024-07-31292902024-08-012025-07-31292902026-09-11292902026-07-31292902025-08-012026-07-31292902025-07-31292902024-07-31jppfs_cor:TreasuryStockMember292902024-08-012025-07-31jppfs_cor:TreasuryStockMember292902024-08-012025-07-31jpcrp_cor:ReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902026-07-31jpcrp_cor:ReportableSegmentsMember292902025-08-012026-07-31jpcrp_cor:ReportableSegmentsMember292902025-08-012026-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902025-07-31jpcrp_cor:ReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:ReconcilingItemsMember292902026-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902026-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902026-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902026-07-31jpcrp_cor:ReconcilingItemsMember292902025-08-012026-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902025-08-012026-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902025-08-012026-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902025-08-012026-07-31jpcrp_cor:ReconcilingItemsMember292902025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902025-07-31jpcrp_cor:ReconcilingItemsMember292902024-08-012025-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902025-08-012026-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902025-08-012026-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902025-08-012026-07-31jppfs_cor:ShareholdersEquityMember292902025-08-012026-07-31jppfs_cor:TreasuryStockMember292902025-08-012026-07-31jppfs_cor:RetainedEarningsMember292902025-08-012026-07-31jppfs_cor:CapitalSurplusMember292902024-07-31jppfs_cor:CapitalStockMember292902024-07-31jppfs_cor:CapitalSurplusMember292902024-07-31jppfs_cor:RetainedEarningsMember292902024-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-07-31jppfs_cor:ShareholdersEquityMember292902024-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902024-08-012025-07-31jppfs_cor:CapitalStockMember292902024-08-012025-07-31jppfs_cor:CapitalSurplusMember292902024-08-012025-07-31jppfs_cor:RetainedEarningsMember292902024-08-012025-07-31jppfs_cor:ShareholdersEquityMember292902024-08-012025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-08-012025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902025-08-012026-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMemberiso4217:JPYxbrli:pure